For CROs

Add the services biotech clients are asking you for.

Ophthalmic studies, advanced omics and automated data pipelines. Built on your infrastructure, then handed over so your team runs them.

What we add

Three services. Take one or all of them. Ophthalmology is our specialism; the omics and automation work apply to any study you run.

Our specialism

Ophthalmic services

Take on the ophthalmic studies biotech clients now send elsewhere. Retina is our hands-on research field; anterior segment and ocular safety are delivered with specialist partners.

  • Disease modelsMacular degeneration, diabetic retinopathy, vein occlusion, geographic atrophy and inherited retinal disease; glaucoma and dry eye
  • Imaging and functionOCT, fundus imaging, electroretinography and visual function endpoints
  • Histology and molecularRetinal morphology, immunohistochemistry and target engagement
  • Ocular safetyToxicology readouts, scoped with specialist partners
Applies to: ophthalmology
New readouts

Advanced omics

Offer the readouts clients now ask for by name, with analysis designed around the biology of each study.

  • Bulk RNA-seqDifferential expression and pathway analysis
  • Single-cell RNA-seqCell types, cell states, cell-specific drug response
  • Spatial transcriptomicsExpression in its tissue context
  • Multimodal integrationOmics linked to imaging and assay data
Applies to: any therapeutic area
Faster delivery

Pipeline automation

Modernise the data processes you already run: raw files to a client-ready report, the same way on every study.

  • IngestYour instruments and formats, agreed at scoping
  • AnalyseThe right statistics for the study design
  • ReportPublication-grade figures, traceable methods
  • Your QC gateYour scientists review and sign off each study
Applies to: any therapeutic area

One study, from bench to report.

We have worked at the bench that makes the data, at the computer that analyses it, and with the sponsors who receive the report. The pipeline is built for all three.

1Protocol and metadataRead first, so the analysis follows the study arms, endpoints and acceptance criteria.
2Every data typeImages, assay readouts and sequencing, each processed the right way.
3The right statisticsMatched to the study design, and applied the same way every time.
4Your QC sign-offYour scientists decide exclusions and approve the results.
5One reportAccurate results, clear figures, and methods that trace every value.
ReproducibleTraceableSigned off by your scientists

Software versions, parameters and random seeds are pinned. Inputs, outputs and approvals are recorded for every run.

Improve what you deliver today

More consistent reports on the services you already sell, with your scientists back at the bench instead of the keyboard.

Expand what you can offer tomorrow

The pipeline is modular, so new readouts like single-cell and spatial plug into the same frame and become new service lines.

How a build runs

Three tracks. Each one ends in something you can use, and you can stop after any of them.

Track 1 · Scope

Find the gap

  • Sponsor work you decline today
  • What your lab already has
  • Which capability pays back first
Track 2 · Build

Stand it up

  • Models, assays, omics workflows
  • Pipeline on your infrastructure
  • Pilot on representative data, end to end
Track 3 · Transfer

Make it yours

  • SOPs and acceptance criteria
  • Staff trained and signed off
  • Qualification agreed with your QA
Yours to sell

What you own

New linesSold to sponsors under your own name
Fewer hiresLess reliance on hiring a permanent specialist
Full know-howMethods, SOPs and the pipeline, transferred to you
60% less timeSaved in early-stage development where AI is built into the work, alongside a higher likelihood of clinical success (Cheng et al., npj Digital Medicine, 2025)

What you end up owning

Built around your systems. Facilities, LIMS, QMS and data systems stay in place. Any changes a build needs are agreed upfront.

Your sponsors stay yours. We don’t run a lab or sell studies. The work is under confidentiality, and any overlap with our biotech advisory clients is declared before we start.

Done before. We built ophthalmic disease models for a global pharmaceutical company bringing its testing in-house.

Ophthalmic studies Omics readouts Automated reports CAPABILITY we ADD models · omics · pipeline · know-how YOUR LAB facilities · staff · QMS · data infrastructure
  1. New service linesOphthalmic studies · omics readouts · automated reports
  2. Capability we addModels · omics · pipeline · know-how
  3. Your labFacilities · staff · QMS · data infrastructure

What the handover includes

  • An agreed workflow, and a specification of the inputs it supports
  • Pilot on representative data or an agreed study
  • Documented methods, software versions and configuration
  • Defined QC checks and scientist approval points
  • Acceptance results against agreed test cases
  • SOPs, training and operating responsibilities
  • Code and method ownership terms, agreed in writing
  • A defined support period and change process

How the engagement works

Start here

Thirty minutes, no charge

No obligation either. Tell us what sponsors ask for that you can’t deliver yet, and we’ll tell you which capability is likely to pay back first.

Nothing locked in

Stop after any track

Each track is scoped and priced before it starts. No retainer and no minimum term. Equipment and consumables are bought by you, at cost, with nothing marked up.

Deliberately limited

A few builds at a time

Transfer takes real attention. We run a small number of builds in parallel, and we’ll say so if we can’t take yours on now.

Where to start

Send us a few details through the form. One free call is usually enough to tell whether a build makes commercial sense for your lab.

Source: H. Cheng et al., Ophthalmic drug discovery and development using artificial intelligence and digital health technologies, npj Digital Medicine, 2025.

Scope a capability build.

Tell us what your sponsors are asking for that you can’t yet deliver. We’ll tell you what it would take to say yes.

Get in touch →

adrian@tractumbio.com

The form takes a minute. A short note on the sponsor requests you are turning away is enough to start, and no confidential data is needed. The first call is thirty minutes, no charge and nothing locked in. We reply within two business days.